Xenon licenses pain compounds and companion diagnostics to Genentech
Executive Summary
Canadian drug discovery company Xenon Pharmaceuticals Inc. has licensed Genentech Inc. exclusive rights to develop and sell drug candidates for pain, including oral inhibitors of the sodium Nav 1.7 channel. Genentech also received a nonexclusive license to companion diagnostics.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Large Molecule
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice